Pankaj R Patel
Overview
Explore the profile of Pankaj R Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, et al.
Pharmacol Res Perspect
. 2020 Aug;
8(4):e00565.
PMID: 32790160
Bruton's tyrosine kinase (BTK) plays a central and pivotal role in controlling the pathways involved in the pathobiology of cancer, rheumatoid arthritis (RA), and other autoimmune disorders. ZYBT1 is a...
2.
Giri P, Delvadia P, Ladani M, Prajapati N, Gupta L, Patel N, et al.
Eur J Pharm Sci
. 2019 Jan;
130:107-113.
PMID: 30633968
Saroglitazar, a PPAR αҮ agonist, is currently undergoing global development for the treatment of NASH and other indications. Saroglitazar showed CYP2C8 inhibition in human liver microsomes (IC: 2.9 μM). The...
3.
Chavda A, Lil N, Patel P
Indian J Orthop
. 2018 Dec;
52(6):631-637.
PMID: 30532304
Background: Floating knee is a condition resulting from high energy trauma usually associated with minor to life threatening injuries making it challanging to treat There are no studies available in...
4.
Giri P, Gupta L, Singh S, Patel N, Srinivas N, Srivastva B, et al.
Xenobiotica
. 2018 Nov;
49(10):1164-1172.
PMID: 30488748
ZYTP1 is a novel Poly (ADP-ribose) polymerase protein inhibitor being developed for cancer indications. The focus of the work was to determine if ZYTP1 had a perpetrator role in the...
5.
Jain M, Joharapurkar A, Patel V, Kshirsagar S, Sutariya B, Patel M, et al.
Eur J Pharmacol
. 2018 Nov;
843:113-120.
PMID: 30458168
Chronic inflammatory diseases are often associated with anemia. In such conditions, anemia is generally treated with erythropoiesis stimulating agents (ESAs) which are associated with potentially hazardous side effects and poor...
6.
Jain M, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, et al.
Cancer Chemother Pharmacol
. 2018 Jul;
82(4):635-647.
PMID: 30046848
Purpose: Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme involved in the detection and repair of DNA damage. Studies have shown that inhibition of PARP and Tankyrase (TNKS) has significant antitumor...
7.
Jain M, Giri S, Bhoi B, Trivedi C, Rath A, Rathod R, et al.
Liver Int
. 2017 Nov;
38(6):1084-1094.
PMID: 29164820
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common clinico-pathological conditions that affect millions of patients worldwide. In this study, the efficacy of saroglitazar, a...
8.
Patel H, Soni K, Trivedi R, Heading H, Geue J, Kansagra K, et al.
Bioanalysis
. 2017 May;
9(9):719-732.
PMID: 28488896
Aim: A sensitive LC-MS/MS method was developed and validated for estimation of ZYAN1 in human blood/urine. Methods: An analog internal standard IOX2 along with ZYAN1 was quantified using selective reaction...
9.
Jain M, Joharapurkar A, Kshirsagar S, Patel V, Bahekar R, Patel H, et al.
Br J Pharmacol
. 2017 Apr;
174(14):2346-2357.
PMID: 28452143
Background And Purpose: Dipeptidyl peptidase (DPP)-4 inhibitors increase levels of glucagon-like peptide-1 (GLP-1) and provide clinical benefit in the treatment of type 2 diabetes mellitus. As longer acting inhibitors have...
10.
Giri P, Patel N, Patel B, Patel H, Bahekar R, Srinivas N, et al.
Biomed Chromatogr
. 2017 Apr;
31(11).
PMID: 28370279
A rapid and highly specific assay was developed and validated for the estimation of ZYDPLA1 in rat plasma using liquid chromatography coupled to tandem mass spectrometry with positive electrospray ionization....